Evotec (ETR:EVT) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Shares of Evotec SE (ETR:EVT) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of €4.28 and traded as low as €3.66. Evotec shares last traded at €3.85, with a volume of 709,422 shares changing hands.

Evotec Trading Down 2.9%

The company has a 50 day simple moving average of €4.25 and a 200 day simple moving average of €4.89. The company has a current ratio of 1.68, a quick ratio of 2.97 and a debt-to-equity ratio of 55.38. The stock has a market capitalization of $639.39 million, a PE ratio of -3.73, a P/E/G ratio of 0.98 and a beta of 1.31.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.